Next Article in Journal
Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response
Next Article in Special Issue
Liver Cell Transformation in Chronic HBV Infection
Previous Article in Journal
Identification of Mouse Cytomegalovirus Resistance Loci by ENU Mutagenesis
Previous Article in Special Issue
Adaptive Immunity to Hepatitis C Virus
Article Menu

Export Article

Open AccessReview
Viruses 2009, 1(3), 484-509; doi:10.3390/v1030484

HBV and HCV Therapy

“A.M. Migliavacca” Center for Liver Disease, First Gastroenterology Unit, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università di Milano, Via F. Sforza 35, 20122 Milan, Italy
Author to whom correspondence should be addressed.
Received: 13 August 2009 / Revised: 8 October 2009 / Accepted: 19 October 2009 / Published: 22 October 2009
(This article belongs to the Special Issue Hepatitis Viruses)
View Full-Text   |   Download PDF [311 KB, uploaded 12 May 2015]   |  


One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.
Keywords: HBV DNA; nucleos(t)ide analogues; Peg-IFN; resistance; HCV RNA; Ribavirin; SVR HBV DNA; nucleos(t)ide analogues; Peg-IFN; resistance; HCV RNA; Ribavirin; SVR
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lampertico, P.; Aghemo, A.; Viganò, M.; Colombo, M. HBV and HCV Therapy. Viruses 2009, 1, 484-509.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top